RARE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $5,115,593.08

Ultragenyx Pharmaceutical Insider Trading History Chart

Ultragenyx Pharmaceutical Share Price & Price History

^$44.22

▲ +0.75 (1.73%)

As of 12/20/2024 06:16 PM ET

Days: 30 | 90 | 365

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

Ultragenyx Pharmaceutical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Emil D Kakkis	CEO	Sell	8,273	$50.00	$413,650.00	2,195,712
10/10/2024	Howard Horn	CFO	Sell	7,465	$52.76	$393,853.40	92,301
9/3/2024	Emil D Kakkis	CEO	Sell	20,000	$55.85	$1,117,000.00	2,223,985
9/3/2024	Theodore Alan Huizenga	CAO	Sell	91	$56.19	$5,113.29	41,551
8/6/2024	Emil D Kakkis	CEO	Sell	20,000	$50.17	$1,003,400.00	2,243,985
7/2/2024	Corsee D. Sanders	Director	Sell	584	$40.98	$23,932.32	12,009
6/12/2024	Karah Herdman Parschauer	EVP	Sell	9,806	$45.00	$441,270.00	57,981
6/10/2024	Corsee D. Sanders	Director	Sell	1,737	$41.10	$71,390.70	7,248
4/18/2024	Eric Crombez	EVP	Sell	142	$44.10	$6,262.20	48,785
3/11/2024	Thomas Richard Kassberg	EVP	Sell	11,509	$49.93	$574,644.37	252,823
3/7/2024	Matthew K. Fust	Director	Sell	12,195	$50.88	$620,481.60	14,860
3/1/2024	John Richard Pinion	Insider	Sell	4,173	$53.76	$224,340.48	89,268
3/1/2024	Karah Herdman Parschauer	EVP	Sell	3,756	$53.76	$201,922.56	67,340
3/1/2024	Theodore Alan Huizenga	CAO	Sell	341	$53.76	$18,332.16	41,380
10/23/2023	Thomas Richard Kassberg	EVP	Sell	39,878	$32.78	$1,307,200.84	246,860
10/19/2023	Emil D Kakkis	CEO	Sell	47,853	$33.52	$1,604,032.56	599,743
9/7/2023	Theodore Alan Huizenga	CAO	Sell	2,163	$40.80	$88,250.40	23,614
9/5/2023	Erik Harris	EVP	Sell	6,000	$37.96	$227,760.00	51,281
9/1/2023	Theodore Alan Huizenga	CAO	Sell	970	$37.15	$36,035.50	23,777
6/30/2023	Corsee D. Sanders	Director	Sell	585	$46.76	$27,354.60	8,985
6/19/2023	Erik Harris	EVP	Sell	305	$48.20	$14,701.00	57,281
6/8/2023	Corsee D. Sanders	Director	Sell	1,485	$51.65	$76,700.25	9,570
5/18/2023	John Richard Pinion	Insider	Sell	2,012	$50.00	$100,600.00	74,744
5/4/2023	Karah Herdman Parschauer	EVP	Sell	4,378	$45.00	$197,010.00	51,982
3/1/2023	Camille L. Bedrosian	EVP	Sell	3,881	$45.25	$175,615.25	46,720
3/1/2023	Dennis Karl Huang	Insider	Sell	389	$45.65	$17,757.85	75,314
2/28/2023	Theodore Alan Huizenga	CAO	Sell	639	$43.40	$27,732.60	15,558
12/21/2022	Theodore Alan Huizenga	CAO	Sell	2,031	$43.96	$89,282.76	16,197
10/14/2022	Mardi Dier	CFO	Sell	1,629	$40.16	$65,420.64	66,695
10/12/2022	Mardi Dier	CFO	Sell	3,484	$38.22	$133,158.48	68,324
6/19/2022	Erik Harris	EVP	Sell	295	$54.78	$16,160.10	36,160
4/16/2022	Theodore Alan Huizenga	CAO	Sell	132	$84.55	$11,160.60	16,914
3/11/2022	Thomas Richard Kassberg	EVP	Sell	10,281	$67.01	$688,929.81
3/7/2022	Karah Herdman Parschauer	EVP	Sell	5,140	$62.95	$323,563.00
3/1/2022	Erik Harris	EVP	Sell	2,713	$66.62	$180,740.06
3/1/2022	John Richard Pinion	Insider	Sell	4,498	$66.62	$299,656.76
1/30/2022	Camille L. Bedrosian	EVP	Sell	1,657	$66.30	$109,859.10

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

SEC Filings (Institutional Ownership Changes) for Ultragenyx Pharmaceutical (NASDAQ:RARE)

97.67% of Ultragenyx Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ultragenyx Pharmaceutical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/19/2024	Principal Financial Group Inc.	86,440	$4.80M	0.0%	+740.0%	0.094%
11/27/2024	Franklin Resources Inc.	218,903	$12.30M	0.0%	-25.5%	0.237%
11/25/2024	Wilmington Savings Fund Society FSB	1,489	$83K	0.0%	N/A	0.002%
11/16/2024	Geode Capital Management LLC	1,571,081	$87.30M	0.0%	+4.4%	1.701%
11/15/2024	M&T Bank Corp	6,992	$0.39M	0.0%	+8.1%	0.008%
11/15/2024	Frazier Life Sciences Management L.P.	633,715	$35.20M	1.4%	+49.1%	0.686%
11/15/2024	Barclays PLC	79,546	$4.42M	0.0%	-66.4%	0.086%
11/15/2024	Public Employees Retirement System of Ohio	32,734	$1.82M	0.0%	-1.6%	0.035%
11/15/2024	Nomura Asset Management Co. Ltd.	1,669	$93K	0.0%	N/A	0.002%
11/15/2024	Y Intercept Hong Kong Ltd	19,151	$1.06M	0.1%	+193.1%	0.021%
11/15/2024	XTX Topco Ltd	14,629	$0.81M	0.1%	+95.2%	0.016%
11/15/2024	Wellington Management Group LLP	4,165,424	$231.39M	0.0%	-8.6%	4.511%
11/15/2024	Two Sigma Advisers LP	987,800	$54.87M	0.1%	+123.4%	1.070%
11/15/2024	Sphera Funds Management LTD.	195,349	$10.85M	1.7%	-33.5%	0.212%
11/15/2024	State Street Corp	2,664,077	$147.99M	0.0%	-1.2%	2.885%
11/15/2024	Stifel Financial Corp	20,961	$1.16M	0.0%	-4.0%	0.023%
11/15/2024	RTW Investments LP	1,968,002	$109.32M	1.6%	-39.6%	2.131%
11/15/2024	Point72 DIFC Ltd	14,517	$0.81M	0.0%	+443.9%	0.016%
11/15/2024	Point72 Asset Management L.P.	653,660	$36.31M	0.1%	+35.9%	0.708%
11/15/2024	Parkman Healthcare Partners LLC	109,468	$6.08M	0.8%	+9.5%	0.119%
11/15/2024	Motley Fool Asset Management LLC	141,649	$8.01M	0.5%	+0.3%	0.153%
11/15/2024	Motley Fool Wealth Management LLC	168,015	$9.33M	0.5%	-1.4%	0.182%
11/15/2024	NFJ Investment Group LLC	38,131	$2.12M	0.1%	-4.4%	0.041%
11/15/2024	Ikarian Capital LLC	179,000	$9.94M	1.3%	N/A	0.194%
11/15/2024	Jacobs Levy Equity Management Inc.	97,960	$5.44M	0.0%	-84.6%	0.106%
11/15/2024	Janus Henderson Group PLC	36,543	$2.03M	0.0%	-49.1%	0.040%
11/15/2024	Cinctive Capital Management LP	15,902	$0.88M	0.0%	-87.4%	0.017%
11/15/2024	Benjamin Edwards Inc.	6,084	$0.34M	0.0%	N/A	0.007%
11/15/2024	Baker BROS. Advisors LP	1,576,114	$87.55M	0.9%	+7.5%	1.707%
11/15/2024	Bamco Inc. NY	48,000	$2.67M	0.0%	N/A	0.052%
11/15/2024	Point72 Hong Kong Ltd	10,020	$0.56M	0.0%	N/A	0.011%
11/15/2024	Erste Asset Management GmbH	15,010	$0.82M	0.0%	N/A	0.016%
11/15/2024	True Wealth Design LLC	778	$43K	0.0%	N/A	0.001%
11/14/2024	PDT Partners LLC	66,193	$3.68M	0.3%	+26.1%	0.072%
11/14/2024	Fred Alger Management LLC	536,298	$29.79M	0.1%	-2.3%	0.581%
11/14/2024	Verition Fund Management LLC	77,306	$4.29M	0.0%	-43.7%	0.084%
11/14/2024	Captrust Financial Advisors	11,428	$0.64M	0.0%	+129.3%	0.012%
11/14/2024	Vestal Point Capital LP	750,000	$41.66M	3.2%	-58.3%	0.812%
11/14/2024	Capstone Investment Advisors LLC	13,089	$0.73M	0.0%	N/A	0.014%
11/14/2024	Suvretta Capital Management LLC	1,151,314	$63.96M	2.0%	-44.1%	1.247%
11/14/2024	Hantz Financial Services Inc.	3,499	$0.19M	0.0%	N/A	0.004%
11/14/2024	Alkeon Capital Management LLC	3,011,716	$167.30M	0.3%	+34.3%	3.261%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	177,756	$9.87M	0.0%	+0.5%	0.192%
11/14/2024	Acuta Capital Partners LLC	25,100	$1.39M	1.1%	N/A	0.027%
11/13/2024	BNP Paribas Financial Markets	28,831	$1.60M	0.0%	-57.3%	0.031%
11/13/2024	FMR LLC	637,821	$35.43M	0.0%	-1.5%	0.691%
11/13/2024	The Manufacturers Life Insurance Company	238,055	$13.22M	0.0%	-3.7%	0.258%
11/12/2024	Pitcairn Co.	10,584	$0.59M	0.0%	-12.1%	0.011%
11/12/2024	Algert Global LLC	73,902	$4.11M	0.1%	+46.9%	0.080%
11/12/2024	Cerity Partners LLC	31,919	$1.77M	0.0%	N/A	0.035%
11/12/2024	Charles Schwab Investment Management Inc.	594,521	$33.03M	0.0%	+10.6%	0.644%
11/12/2024	Massachusetts Financial Services Co. MA	542,373	$30.13M	0.0%	+46.5%	0.587%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	724,182	$40.23M	0.1%	-12.8%	0.786%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	75,265	$4.18M	0.0%	-53.8%	0.082%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	23,817	$1.32M	0.0%	N/A	0.026%
11/7/2024	Quest Partners LLC	2,145	$0.12M	0.0%	N/A	0.002%
11/7/2024	Swiss National Bank	159,152	$8.84M	0.0%	+9.1%	0.173%
11/6/2024	Mutual of America Capital Management LLC	5,780	$0.32M	0.0%	N/A	0.006%
11/6/2024	Natixis Advisors LLC	52,562	$2.92M	0.0%	+290.0%	0.057%
11/6/2024	KBC Group NV	2,568	$0.14M	0.0%	+24.5%	0.003%
11/6/2024	Pier 88 Investment Partners LLC	22,540	$1.25M	0.3%	-13.2%	0.024%
11/6/2024	Angeles Investment Advisors LLC	5,911	$0.33M	0.0%	-11.0%	0.006%
11/5/2024	Victory Capital Management Inc.	10,948	$0.61M	0.0%	+8.8%	0.012%
11/5/2024	GSA Capital Partners LLP	11,508	$0.64M	0.0%	-26.1%	0.012%
11/5/2024	WCM Investment Management LLC	145,349	$7.91M	0.0%	-6.0%	0.158%
11/4/2024	State of New Jersey Common Pension Fund D	34,769	$1.93M	0.0%	-28.7%	0.038%
11/2/2024	Privium Fund Management B.V.	242,512	$13.47M	3.4%	-3.6%	0.263%
11/1/2024	Atria Investments Inc	4,836	$0.27M	0.0%	N/A	0.005%
11/1/2024	Capital Performance Advisors LLP	1,934	$0.11M	0.0%	N/A	0.002%
10/31/2024	Principal Financial Group Inc.	86,440	$4.80M	0.0%	+740.0%	0.104%
10/29/2024	Emerald Advisers LLC	569,798	$31.65M	1.2%	+17.1%	0.685%
10/29/2024	Van ECK Associates Corp	1,487	$81K	0.0%	-23.5%	0.002%
10/29/2024	Emerald Mutual Fund Advisers Trust	429,302	$23.85M	1.2%	+9.9%	0.516%
10/28/2024	Oak Ridge Investments LLC	18,622	$1.03M	0.1%	-3.8%	0.022%
10/28/2024	US Bancorp DE	4,149	$0.23M	0.0%	-41.3%	0.005%
10/25/2024	Pinnacle Associates Ltd.	119,360	$6.63M	0.1%	-25.9%	0.144%
10/25/2024	China Universal Asset Management Co. Ltd.	17,726	$0.99M	0.1%	+81.5%	0.021%
10/25/2024	abrdn plc	253,304	$14.07M	0.0%	-11.0%	0.305%
10/25/2024	Pallas Capital Advisors LLC	10,904	$0.60M	0.0%	N/A	0.013%
10/24/2024	Wealth Enhancement Advisory Services LLC	21,753	$1.21M	0.0%	+195.6%	0.024%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	3,333	$0.18M	0.0%	+34.3%	0.004%
10/23/2024	Values First Advisors Inc.	1,010	$56K	0.0%	N/A	0.001%
10/23/2024	Assenagon Asset Management S.A.	145,433	$8.08M	0.0%	+2.3%	0.158%
10/23/2024	Hennion & Walsh Asset Management Inc.	78,095	$4.34M	0.2%	+6.6%	0.085%
10/22/2024	International Assets Investment Management LLC	10,388	$0.58M	0.0%	+29,580.0%	0.011%
10/19/2024	Allspring Global Investments Holdings LLC	2,287	$0.13M	0.0%	-31.3%	0.002%
10/16/2024	nVerses Capital LLC	2,700	$0.15M	0.1%	+237.5%	0.003%
10/8/2024	CWM LLC	21,332	$1.19M	0.0%	+9,552.5%	0.026%
10/5/2024	Handelsbanken Fonder AB	24,523	$1.36M	0.0%	+15.0%	0.029%
10/3/2024	SG Americas Securities LLC	12,313	$0.68M	0.0%	-22.6%	0.013%
9/16/2024	Point72 DIFC Ltd	2,669	$0.11M	0.0%	-73.4%	0.003%
8/29/2024	Maven Securities LTD	20,000	$0.82M	0.0%	+100.0%	0.024%
8/27/2024	Clearbridge Investments LLC	2,353,804	$96.74M	0.1%	-2.0%	2.831%
8/21/2024	Truist Financial Corp	9,791	$0.40M	0.0%	-3.2%	0.012%
8/16/2024	Clearline Capital LP	32,961	$1.36M	0.0%	N/A	0.036%
8/16/2024	Algert Global LLC	50,322	$2.07M	0.1%	+104.8%	0.055%
8/16/2024	Frazier Life Sciences Management L.P.	425,000	$17.47M	0.8%	N/A	0.461%
8/16/2024	Driehaus Capital Management LLC	528,180	$21.71M	0.2%	+35.7%	0.573%
8/15/2024	Susquehanna Portfolio Strategies LLC	7,147	$0.29M	0.0%	-70.4%	0.008%
8/15/2024	The Manufacturers Life Insurance Company	247,138	$10.16M	0.0%	-14.0%	0.268%

Data available starting January 2016

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $44.22

$42.85

$44.45

50 Day Range

MA: $49.53

$42.94

$57.70

52 Week Range

Now: $44.22

$37.02

$60.37

Volume

1,707,822 shs

Average Volume

782,100 shs

Market Capitalization

$4.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Who are the company insiders with the largest holdings of Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical's top insider shareholders include:
Emil D Kakkis (CEO)
Thomas Richard Kassberg (EVP)
Howard Horn (CFO)
John Richard Pinion (Insider)
Dennis Karl Huang (Insider)
Karah Herdman Parschauer (EVP)
Erik Harris (EVP)
Eric Crombez (EVP)
Camille L Bedrosian (EVP)
Theodore Alan Huizenga (CAO)
Matthew K Fust (Director)
Corazon (Corsee) D Sanders (Director)
Learn More about top insider investors at Ultragenyx Pharmaceutical.
Who are the major institutional investors of Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical's top institutional investors include:
Wellington Management Group LLP — 4.51%
Alkeon Capital Management LLC — 3.26%
State Street Corp — 2.89%
RTW Investments LP — 2.13%
Baker BROS. Advisors LP — 1.71%
Geode Capital Management LLC — 1.70%
Learn More about top institutional investors of Ultragenyx Pharmaceutical stock.
Which major investors are selling Ultragenyx Pharmaceutical stock?: During the last quarter, RARE stock was sold by these institutional investors:
RTW Investments LP
Vestal Point Capital LP
Suvretta Capital Management LLC
Jacobs Levy Equity Management Inc.
Wellington Management Group LLP
Barclays PLC
Cinctive Capital Management LP
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
During the previous year, company insiders that have sold Ultragenyx Pharmaceutical company stock include:
Emil D Kakkis (CEO)
Thomas Richard Kassberg (EVP)
Howard Horn (CFO)
John Richard Pinion (Insider)
Dennis Karl Huang (Insider)
Karah Herdman Parschauer (EVP)
Erik Harris (EVP)
Eric Crombez (EVP)
Camille L Bedrosian (EVP)
Learn More investors selling Ultragenyx Pharmaceutical stock.
Which major investors are buying Ultragenyx Pharmaceutical stock?: During the last quarter, RARE stock was purchased by institutional investors including:
Alkeon Capital Management LLC
Two Sigma Advisers LP
Frazier Life Sciences Management L.P.
Ikarian Capital LLC
Point72 Asset Management L.P.
Massachusetts Financial Services Co. MA
Baker BROS. Advisors LP
Emerald Advisers LLC